Del Prato S, Kahn SE, Pavo I et al (2021) Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial
There have been reports of suicidal thoughts and behaviors in patients using GLP-1 receptor agonists
You may not be eligible if you: Are pregnant, trying to become pregnant, or breastfeeding Have a history of severe allergic reactions to semaglutide or any of the ingredients Are under 18 years old In some cases, Wegovy may not be suitable, including during pregnancy or breastfeeding, or for people with certain medical conditions
Furthermore, we demonstrated in animal studies that GLP-1 secretion induced by these factors does not evoke aversive behaviors, unlike GLP-1RAs, and promotes satiation, thereby suppressing hyperphagia and weight gain induced by a high-fat diet